Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech

< Previous 1 2 3 4 Next >
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Changes to its Leadership Team
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Secures Financing Facilities of Approximately $136 Million
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Appoints Sarah Tanksley as Chief Quality Officer
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
From Alvotech
Via Business Wire
STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab
From Alvotech
Via Business Wire
AVT02, Alvotech’s Biosimilar to High Concentration Formulation of Adalimumab (Humira®) Approved for Use in European Union
From Alvotech
Via Business Wire
Alvotech Beats Back AbbVie’s Trade Secrets Lawsuit
From Alvotech
Via Business Wire
Alvotech Provides Update on FDA Action Regarding AVT02, Proposed High-Concentration Biosimilar to Humira® (adalimumab)
From Alvotech
Via Business Wire
Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira®
From Alvotech
Via Business Wire
Alvotech Announces Positive Top-Line Results for Switching Study Between Proposed Biosimilar AVT02 and Humira®
From Alvotech
Via Business Wire
Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara® (Ustekinumab)
From Alvotech
Via Business Wire
Alvotech Bondholders Convert More Than $100m at Pre-Money Valuation of $2.7bn
From Alvotech
Via Business Wire
Alvotech Reaches Primary Completion Date in Its Switching Study for AVT02, a Proposed Interchangeable Biosimilar to AbbVie’s Humira®
From Alvotech
Via Business Wire
Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.
From Alvotech
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.